Arcus nears crunch time for Gilead opt-in

Arcus nears crunch time for Gilead opt-in

Source: 
EP Vantage
snippet: 

The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?